Literature DB >> 6326896

Absence of lymphocyte ecto-5'-nucleotidase in infants with reticuloendotheliosis and eosinophilia (Omenn's syndrome).

E W Gelfand, D McCurdy, C P Rao, A Cohen.   

Abstract

Lymphocytes from three infants with reticuloendotheliosis and eosinophilia ( Omenn 's syndrome) and immunodeficiency were assayed for 5'-nucleotidase activity. B and T lymphocytes from all three patients were totally deficient in ecto-5'-nucleotidase activity, but had normal levels of cytoplasmic 5'-nucleotidase. In contrast, cultured lymphocytes expressed normal ectoplasmic and cytoplasmic activities, suggesting that the lymphocyte-restricted enzyme deficiency was not likely a primary genetic defect. The deficiency of lymphocyte ecto-5'-nucleotidase was not associated with any abnormality of deoxynucleoside metabolism. The absence of lymphocyte ecto-5'-nucleotidase may be a characteristic feature of this syndrome and may help to distinguish this disease from others with similar manifestations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326896

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Severe pulmonary vascular occlusive disease following bone marrow transplantation in Omenn syndrome.

Authors:  C Brückmann; W Lindner; R Roos; W Permanetter; R J Haas; S G Haworth; B H Belohradsky
Journal:  Eur J Pediatr       Date:  1991-02       Impact factor: 3.183

2.  Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors.

Authors:  W Friedrich; S F Goldmann; W Ebell; R Blütters-Sawatzki; G Gaedicke; A Raghavachar; H H Peter; B Belohradsky; W Kreth; B Kubanek
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

3.  CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73.

Authors:  L Airas; J Hellman; M Salmi; P Bono; T Puurunen; D J Smith; S Jalkanen
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.